Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients With Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

Trial Profile

Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients With Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Pixantrone (Primary) ; Bendamustine; Rituximab
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 17 Nov 2014 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
    • 17 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top